{"id":"https://openalex.org/W2162139090","doi":"https://doi.org/10.1248/bpb.b15-00103","title":"Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia","display_name":"Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia","alternate_titles":[],"publication_year":2015,"publication_date":"2015-01-01","ids":{"openalex":"https://openalex.org/W2162139090","doi":"https://doi.org/10.1248/bpb.b15-00103","mag":"2162139090","pmid":"https://pubmed.ncbi.nlm.nih.gov/25947908"},"language":"en","primary_location":{"id":"doi:10.1248/bpb.b15-00103","doi":"https://doi.org/10.1248/bpb.b15-00103","is_oa":true,"landing_page_url":"https://doi.org/10.1248/bpb.b15-00103","pdf_url":"https://www.jstage.jst.go.jp/article/bpb/38/5/38_b15-00103/_pdf","source":{"id":"https://openalex.org/S165235614","display_name":"Biological and Pharmaceutical Bulletin","issn_l":"0918-6158","issn":["0918-6158","1347-5215"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310313382","host_organization_name":"Pharmaceutical Society of Japan","host_organization_lineage":["https://openalex.org/P4310313382"],"host_organization_lineage_names":["Pharmaceutical Society of Japan"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological &amp; Pharmaceutical Bulletin","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2162139090"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.jstage.jst.go.jp/article/bpb/38/5/38_b15-00103/_pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086680208","display_name":"Masatomo Miura","orcid":"https://orcid.org/0000-0001-7120-2425","observed_orcids":["https://orcid.org/0000-0001-7120-2425"]},"institutions":[{"id":"https://openalex.org/I4210132405","display_name":"Akita University Hospital","ror":"https://ror.org/02szmmq82","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210132405"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Masatomo Miura","raw_affiliation_strings":["Department of Pharmacy, Akita University Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Akita University Hospital","institution_ids":["https://openalex.org/I4210132405"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5086680208"],"corresponding_institution_ids":["https://openalex.org/I4210132405"],"apc_list":null,"apc_paid":null,"fwci":1.6306,"has_fulltext":true,"cited_by_count":168,"citation_normalized_percentile":{"value":0.84631918,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"38","issue":"5","first_page":"645","last_page":"654"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9067000150680542,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9067000150680542,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.05939999967813492,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.003599999938160181,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/therapeutic-drug-monitoring","display_name":"therapeutic drug monitoring","score":0.9509999752044678},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.9670000076293945},{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":1.0},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9679999947547913},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9890000224113464},{"id":"https://openalex.org/keywords/philadelphia-chromosome-positive-leukemia","display_name":"Philadelphia chromosome-positive leukemia","score":0.7009999752044678},{"id":"https://openalex.org/keywords/trough-concentration","display_name":"trough concentration","score":0.8809999823570251},{"id":"https://openalex.org/keywords/ugt1a1-genotype","display_name":"UGT1A1 genotype","score":0.7770000100135803},{"id":"https://openalex.org/keywords/elevated-bilirubin","display_name":"bilirubin elevation","score":0.7360000014305115},{"id":"https://openalex.org/keywords/pleural-effusion","display_name":"pleural effusion","score":0.8370000123977661},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.6909999847412109},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7540000081062317},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.40799999237060547}],"concepts":[{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.9561924338340759},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9239245057106018},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.8650386929512024},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.7553186416625977},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5869506597518921},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.541091799736023},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5172156095504761},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4941258728504181},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4912819266319275},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.485501766204834},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.4638422131538391},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.46145614981651306},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.44077837467193604},{"id":"https://openalex.org/C2780272996","wikidata":"https://www.wikidata.org/wiki/Q1261151","display_name":"Therapeutic drug monitoring","level":3,"score":0.43947505950927734},{"id":"https://openalex.org/C140206745","wikidata":"https://www.wikidata.org/wiki/Q5308895","display_name":"Drug holiday","level":3,"score":0.43073537945747375},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.36956125497817993},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.365040123462677},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.266559362411499},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2511460781097412},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.18351632356643677},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1228201687335968},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000069439","descriptor_name":"Dasatinib","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069439","descriptor_name":"Dasatinib","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000069439","descriptor_name":"Dasatinib","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000069439","descriptor_name":"Dasatinib","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1248/bpb.b15-00103","doi":"https://doi.org/10.1248/bpb.b15-00103","is_oa":true,"landing_page_url":"https://doi.org/10.1248/bpb.b15-00103","pdf_url":"https://www.jstage.jst.go.jp/article/bpb/38/5/38_b15-00103/_pdf","source":{"id":"https://openalex.org/S165235614","display_name":"Biological and Pharmaceutical Bulletin","issn_l":"0918-6158","issn":["0918-6158","1347-5215"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310313382","host_organization_name":"Pharmaceutical Society of Japan","host_organization_lineage":["https://openalex.org/P4310313382"],"host_organization_lineage_names":["Pharmaceutical Society of Japan"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological &amp; Pharmaceutical Bulletin","raw_type":"journal-article"},{"id":"pmid:25947908","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25947908","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological & pharmaceutical bulletin","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1248/bpb.b15-00103","doi":"https://doi.org/10.1248/bpb.b15-00103","is_oa":true,"landing_page_url":"https://doi.org/10.1248/bpb.b15-00103","pdf_url":"https://www.jstage.jst.go.jp/article/bpb/38/5/38_b15-00103/_pdf","source":{"id":"https://openalex.org/S165235614","display_name":"Biological and Pharmaceutical Bulletin","issn_l":"0918-6158","issn":["0918-6158","1347-5215"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310313382","host_organization_name":"Pharmaceutical Society of Japan","host_organization_lineage":["https://openalex.org/P4310313382"],"host_organization_lineage_names":["Pharmaceutical Society of Japan"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological &amp; Pharmaceutical Bulletin","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G2871816645","display_name":"Therapeutic drug management of tyrosine kinase inhibitor","funder_award_id":"23590168","funder_id":"https://openalex.org/F4320334764","funder_display_name":"Japan Society for the Promotion of Science"},{"id":"https://openalex.org/G5334244712","display_name":"Development of a new treatment strategy using TDM for next generation anticancer drug","funder_award_id":"26460188","funder_id":"https://openalex.org/F4320334764","funder_display_name":"Japan Society for the Promotion of Science"},{"id":"https://openalex.org/G6096940294","display_name":"Therapeutic drug management of the novel agents for multiple myeloma","funder_award_id":"26461414","funder_id":"https://openalex.org/F4320334764","funder_display_name":"Japan Society for the Promotion of Science"}],"funders":[{"id":"https://openalex.org/F4320323532","display_name":"Hirosaki University","ror":"https://ror.org/02syg0q74"},{"id":"https://openalex.org/F4320334764","display_name":"Japan Society for the Promotion of Science","ror":"https://ror.org/00hhkn466"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2162139090.pdf","grobid_xml":"https://content.openalex.org/works/W2162139090.grobid-xml"},"referenced_works_count":76,"referenced_works":["https://openalex.org/W42625690","https://openalex.org/W1870190716","https://openalex.org/W1963636200","https://openalex.org/W1964181017","https://openalex.org/W1966814962","https://openalex.org/W1968050802","https://openalex.org/W1968747503","https://openalex.org/W1971392962","https://openalex.org/W1975505029","https://openalex.org/W1977389958","https://openalex.org/W1978821257","https://openalex.org/W1980663284","https://openalex.org/W1981251869","https://openalex.org/W1987060661","https://openalex.org/W1988837929","https://openalex.org/W1991593432","https://openalex.org/W1993702149","https://openalex.org/W1994327535","https://openalex.org/W1998262432","https://openalex.org/W1999026822","https://openalex.org/W2003278476","https://openalex.org/W2013829602","https://openalex.org/W2014933948","https://openalex.org/W2016809033","https://openalex.org/W2018358459","https://openalex.org/W2018627521","https://openalex.org/W2019633460","https://openalex.org/W2023187096","https://openalex.org/W2028959752","https://openalex.org/W2031630811","https://openalex.org/W2042814016","https://openalex.org/W2048536578","https://openalex.org/W2048773586","https://openalex.org/W2050207895","https://openalex.org/W2050646947","https://openalex.org/W2050671905","https://openalex.org/W2055515709","https://openalex.org/W2057114258","https://openalex.org/W2057206328","https://openalex.org/W2058216377","https://openalex.org/W2061681412","https://openalex.org/W2062933371","https://openalex.org/W2068523650","https://openalex.org/W2068639674","https://openalex.org/W2072374370","https://openalex.org/W2073587057","https://openalex.org/W2075706560","https://openalex.org/W2076678352","https://openalex.org/W2077875136","https://openalex.org/W2080241329","https://openalex.org/W2093616162","https://openalex.org/W2097799776","https://openalex.org/W2107262592","https://openalex.org/W2117356576","https://openalex.org/W2118017966","https://openalex.org/W2124524221","https://openalex.org/W2125166778","https://openalex.org/W2126579741","https://openalex.org/W2127754229","https://openalex.org/W2132656575","https://openalex.org/W2133287244","https://openalex.org/W2135939926","https://openalex.org/W2143939343","https://openalex.org/W2150914452","https://openalex.org/W2159146649","https://openalex.org/W2160502345","https://openalex.org/W2162340188","https://openalex.org/W2163773009","https://openalex.org/W2166270808","https://openalex.org/W2168332302","https://openalex.org/W2171188310","https://openalex.org/W2322536880","https://openalex.org/W2414180589","https://openalex.org/W2586689352","https://openalex.org/W2594322701","https://openalex.org/W4213392987"],"related_works":["https://openalex.org/W4389244561","https://openalex.org/W2992140091","https://openalex.org/W2518976338","https://openalex.org/W2951858809","https://openalex.org/W4410695998","https://openalex.org/W2264704452","https://openalex.org/W2609843407","https://openalex.org/W1993702149","https://openalex.org/W2552508548","https://openalex.org/W2026325859"],"abstract_inverted_index":{"Imatinib,":[0],"nilotinib,":[1],"and":[2,41,88,109,188,242],"dasatinib":[3],"are":[4],"tyrosine":[5],"kinase":[6],"inhibitors":[7],"(TKIs)":[8],"that":[9,174],"have":[10],"become":[11],"first-line":[12],"treatments":[13],"for":[14,58,71,81,150],"Philadelphia":[15],"chromosome-positive":[16],"chronic":[17],"myeloid":[18],"leukemia":[19],"(CML).":[20],"According":[21],"to":[22,84,105,113,143,183,196,238,243],"European":[23],"LeukemiaNet":[24],"recommendations,":[25],"the":[26,54,59,153,213,227,240,245],"clinical":[27,91,186,217],"response":[28,50,108,187],"of":[29,62,138,146,164,206,225,247],"CML":[30,72],"patients":[31,45,122,151],"receiving":[32],"TKI":[33,63,69,228],"therapy":[34,70],"should":[35,99,230],"be":[36,66,100,200,231],"evaluated":[37],"after":[38],"3,":[39],"6,":[40],"12":[42],"months.":[43],"For":[44,121,169],"not":[46],"achieving":[47],"a":[48,78,86,107,124,134,160,175,185,189,222],"satisfactory":[49],"within":[51],"3":[52],"months,":[53],"mean":[55],"plasma":[56,95,236],"concentration":[57,97],"three":[60],"months":[61],"administration":[64,205],"must":[65],"considered.":[67],"In":[68],"patients,":[73],"therapeutic":[74],"drug":[75],"monitoring":[76],"is":[77,141,167,172],"new":[79],"strategy":[80],"dosage":[82,224,229],"optimization":[83],"obtain":[85,106,184],"faster":[87],"more":[89],"effective":[90],"response.":[92],"The":[93],"imatinib":[94],"trough":[96],"(C\u2080)":[98],"set":[101],"above":[102],"1000":[103],"ng/mL":[104,112,140,166],"below":[110],"3000":[111],"avoid":[114,197],"serious":[115],"adverse":[116,248],"events":[117],"such":[118],"as":[119],"neutropenia.":[120],"with":[123,152],"UGT1A1*6/*6,":[125],"*6/*28,":[126],"or":[127,178],"*28/*28":[128],"genotype":[129],"initially":[130,156],"administered":[131,157],"300-400":[132],"mg/d,":[133,159],"target":[135,161,235],"nilotinib":[136,162],"C\u2080":[137,163,191],"500":[139],"recommended":[142,173],"prevent":[144],"elevation":[145],"bilirubin":[147],"levels,":[148],"whereas":[149],"UGT1A1*1":[154],"allele":[155],"600":[158],"800":[165],"recommended.":[168],"dasatinib,":[170],"it":[171],"higher":[176],"Cmax":[177],"C\u2082":[179],"(above":[180],"50":[181],"ng/mL)":[182,195],"lower":[190],"(less":[192],"than":[193],"2.5":[194],"pleural":[198],"effusion":[199],"maintained":[201],"by":[202,221],"once":[203],"daily":[204],"dasatinib.":[207],"Although":[208],"at":[209],"present":[210],"clinicians":[211],"consider":[212],"next":[214],"pharmacotherapy":[215],"from":[216],"responses":[218],"(efficacy/toxicity)":[219],"obtained":[220],"fixed":[223],"TKI,":[226],"adjusted":[232],"based":[233],"on":[234],"concentrations":[237],"maximize":[239],"efficacy":[241],"minimize":[244],"incidence":[246],"events.":[249]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2162139090","counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":14},{"year":2024,"cited_by_count":16},{"year":2023,"cited_by_count":17},{"year":2022,"cited_by_count":16},{"year":2021,"cited_by_count":22},{"year":2020,"cited_by_count":17},{"year":2019,"cited_by_count":23},{"year":2018,"cited_by_count":10},{"year":2017,"cited_by_count":14},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
